PM4 - Impact of Enhanced Recovery after Surgery Program on Postoperative Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Saturday, February 15, 2020

10:45 AM – 11:00 AM

Location: Sebastian I 1/2

Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been associated with increased postoperative complications. We report on our experience following implementation of an Enhanced Recovery After Surgery (ERAS) program for CRS and HIPEC.

Methods: Patients were divided into pre- and post-ERAS groups. Implementation of the ERAS program included pre-operative carbohydrate loading, goal-directed fluid management, intraoperative lidocaine infusion, minimizing the use of narcotics, and nasogastric tubes, and early mobilization and feeding.

Results: Of a total of 157 procedures, 88 (56%) were in the pre-ERAS group and 69 (44%) were in the ERAS group. There was no difference in age, sex, comorbidities, peritoneal carcinomatosis index, completeness of cytoreduction, or operative time between the two groups. ERAS patients received less total fluids intraoperatively (4204 cc ± 2044 vs. 6451cc ± 3530, p=0.001). Mean length of stay (LOS) was reduced from 10.1 ± 4.5 days to 7.9 ± 6.7 days (p = 0.024) and the rate of grade ≥ III Clavien-Dindo complications was reduced from 38.6% to 23.1% (p = 0.39) following ERAS implementation without affecting readmission rate (13.6% vs. 17.4%, p=0.519).

Conclusions: Implementation of an ERAS program in patients undergoing CRS and HIPEC is associated with a reduction in overall major complications and LOS.

Oral Abstract Presenter(s)

George Salti, MD

Chief of Surgical Oncology, University of Illinois at Chicago Chief of Surgical Oncology, Edward-Elmhurst Health
Edward-Elmhurst Health
Naperville, Illinois, United States

Disclosure: Disclosure information not submitted.